Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,115,637 papers from all fields of science
Search
Sign In
Create Free Account
Neovastat
Known as:
Neovastat/AE-941
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
AE-941
Shark cartilage extract
GW786034
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
B. Escudier
,
T. Choueiri
,
+10 authors
R. Bukowski
The Journal of urology
2007
Corpus ID: 1236909
Highly Cited
2004
Highly Cited
2004
Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue
É. Dupont
,
P. Falardeau
,
+4 authors
M. Alaoui-Jamali
Clinical & Experimental Metastasis
2004
Corpus ID: 27643318
A novel naturally occurring antiangiogenic agent isolated from cartilage, referred to as Neovastat (Æ-941), was examined for its…
Expand
2004
2004
The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity
D. Gingras
,
D. Labelle
,
+4 authors
R. Béliveau
Investigational New Drugs
2004
Corpus ID: 20224764
The plasminogen activator/plasmin system represents a key component of the proteolytic machinery underlying angiogenesis. In this…
Expand
Highly Cited
2003
Highly Cited
2003
Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells.
B. Annabi
,
S. Thibeault
,
+5 authors
R. Béliveau
Experimental hematology
2003
Corpus ID: 6622042
Highly Cited
2003
Highly Cited
2003
Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer.
J. Latreille
,
G. Batist
,
+7 authors
É. Dupont
Clinical lung cancer
2003
Corpus ID: 23519964
AE-941 (Neovastat), an antiangiogenic component extracted from cartilage, selectively competes for the binding of vascular…
Expand
Highly Cited
2002
Highly Cited
2002
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
G. Batist
,
F. Patenaude
,
+5 authors
É. Dupont
Annals of oncology : official journal of the…
2002
Corpus ID: 4681226
BACKGROUND renal cell carcinoma (RCC) is a potential target for anti-angiogenic drugs because of its high vascularization…
Expand
Highly Cited
2002
Highly Cited
2002
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.
D. Boivin
,
Sébastien P. Gendron
,
É. Beaulieu
,
D. Gingras
,
R. Béliveau
Molecular cancer therapeutics
2002
Corpus ID: 35026918
Neovastat (AE-941), a naturally occurring multifunctional antiangiogenic agent, has been shown to inhibit key components of the…
Expand
Highly Cited
2002
Highly Cited
2002
Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis.
D. Sauder
,
J. DeKoven
,
P. Champagne
,
D. Croteau
,
É. Dupont
Journal of the American Academy of Dermatology
2002
Corpus ID: 27947709
There is considerable evidence to support an immunopathogenic basis of psoriasis. However, changes such as altered angiogenesis…
Expand
Highly Cited
2002
Highly Cited
2002
The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.
Michael H. Weber
,
Joanne Lee
,
F. Orr
International journal of oncology
2002
Corpus ID: 5859415
Bone metastases are generally associated with bone destruction which occurs in response to factors secreted by metastatic cells…
Expand
Highly Cited
2002
Highly Cited
2002
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
R. Béliveau
,
D. Gingras
,
+15 authors
É. Dupont
Clinical cancer research : an official journal of…
2002
Corpus ID: 21607296
PURPOSE Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, which exerts direct effects on vascular…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE